Training in Cardiovascular Translational Research

项目总结/摘要 该申请要求继续资助博士前（6个插槽，增加2个插槽）和博士后， 博士（4个名额，保持不变）培训补助金，题为“心血管转化 研究“。目标是培养未来的CV科学家，他们拥有将基础发现从 通过开发新的治疗方法将实验室转化为临床实践。创新的关键是 课程涵盖成功的治疗发现，验证和治疗所需的主要学科。 开发包括：1）CV疾病的基本机制/靶点识别; 2）靶点给药/高 通量筛选; 3）使用人类疾病的相关动物模型的目标验证/概念验证; 4)药物化学介绍-化合物/生物制剂的优化; 5）药物化学的基本概念 知识产权保护; 6）药物药理学基础; 6）毒理学基础; 7） 从临床前到IND申报的药物开发原则; 8）临床试验的基本原理。一个新 这个非常成功的项目的一个重要方面是基于结构的心血管药物发现。 教师导师指导四个主要领域的研究培训：1）CV信号的结构生物学 分子，包括离子通道和G蛋白偶联受体的解析结构; 2）CV的生物物理学 细胞信号传导，包括离子通道、心脏和平滑肌信号传导; 3）CV动物模型 疾病，包括心力衰竭、心律失常、动脉粥样硬化和糖尿病的小鼠模型;以及4） 临床转化CV科学，包括人类干细胞的综合利用，心血管遗传学 疾病、生物材料支架和生物反应器、临床电生理学和心力衰竭。另一 创新为博士前和博士后学员提供临床接触/培训， 在心脏病学研究员的监督下，在医院开展活动， 他们的基础研究与人类CV疾病的相关性。学员申请独立资助继续 经过两年的资助，博士前候选人是从一个大型和多样化的选择 哥伦比亚大学医学中心的7个研究生课程的优秀申请者池─细胞 生理学和生物物理学，生物化学和分子生物物理学，病理学和细胞生物学， 综合课程，营养和代谢生物学，药理学和分子信号。博士后 候选人是从大量的直接申请人中挑选出来的。持续努力 招募妇女和少数民族的工作继续取得成功。该培训计划提供心血管 研讨会系列，期刊俱乐部，联合实验室会议和务虚会，促进合作， 跨学科研究该计划利用了哥伦比亚现有的许多优势 大学，包括欧文临床和转化研究中心（CTSA），梅尔曼学院 公共卫生，基因组中心，生物信息学，组织和生物医学工程。

Project Summary/Abstract This application requests continued funding for a pre-doctoral (6 slots, an increase of 2 slots) and post- doctoral (4 slots, remains the same) training grant entitled, `Training in Cardiovascular Translational Research'. The goal is to train future CV scientists who have expertise in bringing basic discoveries from the laboratory into clinical practice through development of novel therapeutics. The KEY INNOVATION is a course covering the major disciplines required for successful therapeutics discovery, validation and development including: 1) basic mechanisms in CV diseases/target identification; 2) drugging the target/high throughput screening; 3) target validation/proof of concept using relevant animal models of human disease; 4) introduction to medicinal chemistry – optimization of compounds/biologicals; 5) basic concepts of intellectual property protection; 6) fundamentals of medical pharmacology; 6) basics in toxicology; 7) principals of drug development from pre-clinical to IND filing; 8) fundamentals of clinical testing. A new dimension to this highly successful program focuses on structure-based cardiovascular drug discovery. Faculty mentors direct research training in four primary areas: 1) Structural Biology of CV Signaling Molecules, including solving structures of ion channels and G-protein coupled receptors; 2) Biophysics of CV Cell Signaling, including ion channels, cardiac and smooth muscle signaling; 3) Animal Models of CV Diseases, including mice models of heart failure, cardiac arrhythmias, atherosclerosis, and diabetes; and 4) Clinical-Translational CV Sciences, including integrated use of human stem cells, genetics of cardiovascular diseases, biomaterial scaffolds and bioreactors, clinical electrophysiology, and heart failure. Another innovation provides clinical exposure/training for pre- and postdoctoral trainees who are introduced to clinical activities in the hospital under the supervision of cardiology fellows in order to gain appreciation of the relevance of their basic research to human CV disease. Trainees apply for independent funding to continue their training after two years of grant support. Pre-doctoral candidates are selected from a large and diverse pool of outstanding applicants to 7 graduate programs at Columbia University Medical Center─ Cellular Physiology and Biophysics, Biochemistry and Molecular Biophysics, Pathology and Cell Biology, the Integrated Program, Nutritional and Metabolic Biology, Pharmacology and Molecular Signaling. Post-doctoral candidates are selected from a large applicant pool of direct applicants to program faculty. Ongoing efforts to recruit of woman and minorities continue to be successful. The training program provides cardiovascular seminar series, journal clubs, joint laboratory meetings and retreats that foster collaborations and interdisciplinary research. The program takes advantage of the many existing strengths of Columbia University, including the Irving Center for Clinical and Translational Research (CTSA), Mailman School of Public Health, Genome Center, Bioinformatics, and Tissue and Biomedical Engineering.